In NSCLC, drugs such as gefitinib and erlotinib target the epidermal growth factor receptor (EGFR) pathway, which is frequently altered in solid tumors, leading to enhanced tumor sensitivity and reduced aggressiveness [16]. The gene discussed is EGFR; the disease is neoplasm.